Table 1. Seropositive rates of 17 patients with COVID-19 according to days post symptom onset.
| Days post symptom onset | IgM | IgG | ||
|---|---|---|---|---|
| AFIAS | ELISA | AFIAS | ELISA | |
| 01-Jul | 12.50% | 12.50% | 12.50% | 0.00% |
| (N = 8)1 | (1/8) | (1/8) | (1/8) | (0/8) |
| Aug-14 | 37.50% | 14.30% | 57.10% | 35.70% |
| (N = 14) | (3/8) | (2/14) | (8/14) | (5/14) |
| 15–21 | 54.50% | 72.70% | 90.90% | 90.90% |
| (N = 11) | (6/11) | (8/11) | (10/11) | (10/11) |
| 22–35 | 33.50% | 33.50% | 100.00% | 100.00% |
| (N = 6) | (2/6) | (2/6) | (6/6) | (6/6) |
| 36–49 | 25.00% | 12.50% | 100.00% | 87.50% |
| (N = 8) | (2/8) | (1/8) | (8/8) | (7/8) |
| >50 | 0.00% | 33.30% | 100.00% | 100.00% |
| (N = 3) | (0/3) | (1/3) | (3/3) | (3/3) |
Abbreviation: COVID-19, coronavirus disease 2019; AFIAS, AFIAS COVID-19 Ab (Boditech Med Inc., Chuncheon, Republic of Korea); ELISA, EDI™ Novel Coronavirus COVID-19 IgG/IgM ELISA Kit (Epitope Diagnostics, Inc., San Diego, CA)
1Number of patients